On Tuesday, we covered Compass Pathways’ readout covering 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD): Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch. After our initial reporting published, the company shared more detailed slides (PDF) as well as prepared remarks on a webcast, which was followed by analyst Q&
